Drugs / Autologous CAR19 T lymphocytes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05054257 | Jun 2021 → Jun 2025 overdue | B-cell acute lymphoblastic leukemia | Institute of Hematology and Blood Transfusion, Czech Republic | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous CAR19 T lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05054257 ↗ |
| Known as | CART19 | “Following lymphodepleting conditioning regimen, the patients will receive a single dose of autologous CAR19 T lymphocytes provided by the sponsor´s manufacturing facility....” NCT05054257 ↗ |
| Modality | Cell therapy | “autologous CAR19 T lymphocytes” NCT05054257 ↗ |
| Target | CD19 | “Chimeric Antigen Receptor Specific to CD19” NCT05054257 ↗ |